Clinical Trial Update: Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating reirradiation with pembrolizumab for locoregional inoperable recurrence or second primary head and neck squamous cell carcinoma has com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Dan Zandberg | Conditions: Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Status: COMPLETED | Results posted: 2025-03-06